Effects of the chemotherapeutic agents for non-hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome

被引:34
|
作者
Vaisheva, Farida
Delbes, Geraldine
Hales, Barbara F.
Robaire, Bernard
机构
[1] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada
[2] McGill Univ, Dept Obstet & Gynecol, Montreal, PQ, Canada
来源
JOURNAL OF ANDROLOGY | 2007年 / 28卷 / 04期
关键词
anticancer drugs; spermatogenesis; male germ cell; apoptosis; adverse effects; developmental toxicity;
D O I
10.2164/jandrol.106.002428
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Chemotherapy of non-Hodgkin lymphoma (NHL) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is associated with significant gonadal damage. Our goal was to determine the impact of CHOP chemotherapy on the male reproductive system, fertility, and progeny outcome in the rat model. Adult male Sprague-Dawley rats received saline or CHOP, 4 cycles of 3 weeks each, at doses analogous to 1/3 x, 2/3 x, or 1 x the human dose; males were mated to evaluate effects on progeny outcome. Reproductive organ weights were significantly decreased in the 1 x CHOP-exposed group. The spermatozoal contents of the testes and epididymides were decreased in 1 X CHOP-treated males; the 1/3 x and 2/3 x doses also affected testicular sperm contents. Seminiferous tubule diameters were decreased by 20% in 1 X CHOP-treated males. Damage ranged from the presence of small vacuoles in the epithelium to tubules deprived of spermato- cytes and spermatids and was accompanied by an increased incidence of germ cell apoptosis. The acridine orange assay revealed a significant increase in sperm with abnormal DNA integrity profiles in the 1 X CHOP group. Despite effects on germ cell number and quality, CHOP-exposed rats remained fertile. However, a 50% decrease in live fetuses was observed in litters sired by 1 x CHOP-treated males due to a significant increase in both pre-implantation and postimplantation losses; postimplantation loss was also elevated among litters sired by 2/3 X CHOP-treated males. Thus, CHOP treatment affected both the quantity and quality of male germ cells; conceptal loss is a sensitive measure of the integrity of the male genome.
引用
收藏
页码:578 / 587
页数:10
相关论文
共 50 条
  • [1] Reversibility of the effects of the chemotherapeutic regimen for non-Hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone, on the male rat reproductive system and progeny outcome
    Delbes, Geraldine
    Vaisheva, Farida
    Luu, Trang
    Marcon, Ludovic
    Hales, Barbara F.
    Robaire, Bernard
    REPRODUCTIVE TOXICOLOGY, 2010, 29 (03) : 332 - 338
  • [2] Effects of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) on the male rat reproductive system and progeny outcome
    Vaisheva, F
    Delbes, G
    Hales, BF
    Robaire, B
    JOURNAL OF ANDROLOGY, 2006, : 88 - 88
  • [3] Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma
    R. I. Fisher
    Cancer Chemotherapy and Pharmacology, 1997, 40 : S42 - S46
  • [4] Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma
    Fisher, RI
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (Suppl 1) : S42 - S46
  • [5] TREATMENT OF DIFFUSE HISTIOCYTIC AND DIFFUSE MIXED NON-HODGKIN LYMPHOMAS WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP)
    COHEN, Y
    EPELBAUM, R
    BENSHAHAR, M
    RON, Y
    HAIM, N
    ACTA ONCOLOGICA, 1988, 27 (05) : 531 - 535
  • [6] Efficacy of fludarabine, mitoxantrone, dexamethasone alternating with cyclophosphamide, doxorubicin, vincristine and prednisone (FMD/CHOP) in bulky follicular non-Hodgkin's lymphoma
    Wilder, DD
    Ogden, JL
    Jain, VK
    BLOOD, 2001, 98 (11) : 603A - 603A
  • [7] Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index
    Aydin, F
    Ulusoy, S
    Ovali, E
    JOURNAL OF CHEMOTHERAPY, 1997, 9 (06) : 446 - 451
  • [8] Successful treatment of diffuse large B-cell non-Hodgkin lymphoma with modified CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and rituximab in a patient with Nijmegen syndrome
    Dumic, Miroslav
    Radman, Ivo
    Krnic, Nevena
    Nola, Marin
    Kusec, Rajko
    Begovic, Davor
    Labar, Boris
    Rados, Marko
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (09): : 590 - 593
  • [9] COMBINATION CHEMOTHERAPY OF ADVANCED NON-HODGKIN LYMPHOMA WITH BLEOMYCIN, ADRIAMYCIN, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISONE (BACOP)
    SKARIN, AT
    ROSENTHAL, DS
    MOLONEY, WC
    FREI, E
    BLOOD, 1977, 49 (05) : 759 - 770
  • [10] Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis
    Linschoten, Marijke
    Kamphuis, Janine A. M.
    Van Rhenen, Anna
    Bosman, Laurens P.
    Cramer, Maarten J.
    Doevendans, Pieter A.
    Teske, Arco J.
    Asselbergs, Folkert W.
    LANCET HAEMATOLOGY, 2020, 7 (04): : E295 - E308